Empatica, a pioneer in digital biomarker development and patient monitoring using wearables and AI, today unveiled ...

Glucotrack reported positive clinical results for its implantable glucose monitor, aiming to offer a less-intrusive option ...

Duchenne muscular dystrophy is characterized by a mutation in the DMD gene that leads to a lack of dystrophin and muscle loss ...

GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with ...

Vidhu Thaker, M.D., Pediatric Endocrinology, Columbia University, New York City will present a poster from the 14-week, multicenter, international, randomized, double-blind, placebo-controlled Phase 2 ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

The cumulative data from the Phase 1 study indicate that salanersen has a generally well tolerated safety profile at both the 40 mg and 80 mg doses, with most adverse events (AEs) mild to moderate in ...

This updated asthma guideline establishes a consistent approach to improving asthma diagnosis and control in adults and ...

The American Diabetes Association's McCormick Place event was also a bit of a coming out party for North Chicago-based Abbott's new head of diabetes business.

After three and half years of intensive negotiations and 13 rounds of meetings the 78th World Health Assembly (WHA), the WHO’s peak decision-making body (comprising of all of 194 sovereign member ...

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene ...